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The Diabetes Control and Complications Trial (DCCT) involved intensive diabetes therapy of subjects with type 1 diabetes
mellitus (T1DM) for an average period of 6.5 years. A subset of these subjects gained excessive weight. We tested for association of
polymorphisms in 8 candidate genes with the above trait. We found the Gly482Ser polymorphism in the peroxisome proliferator-
activated receptor γ coactivator-1α (PGC1α) to be signiﬁcantly associated with weight gain in males (P = .0045) but not in
females. The Ser allele was associated with greater weight gain than the Gly allele (P = .005). Subjects with a family history of
type 2 diabetes mellitus (T2DM) were more common among those who gained excessive weight. We conclude that T2DM and the
Gly482Ser polymorphism in PGC1α contribute to the eﬀect of intensive diabetes therapy on weight gain in males with T1DM.
Copyright © 2009 S. S. Deeb and J. D. Brunzell.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
ThemajorcomplicationsofT1DMaremicrovasculardisease
leading to visual impairment and nephropathy, as well
as premature cardiovascular disease [1]. The DCCT was
designed as a randomized prospective trial to evaluate
the beneﬁts of intensive diabetes therapy compared with
conventional therapy [2]. After a mean of 6.5 years of
intensive diabetes therapy there was a reduction in retinopa-
thy, nephropathy, and neuropathy. Two negative outcomes
of intensive diabetes therapy were a threefold increase of
episodes of severe hypoglycemia [2] and marked weight
gain in a subset of individuals [3]. However, it was shown
that the increase in incidence of severe hypoglycemia did
not account for excessive weight gain [4]. The top quartile
(Q4) of increase in body mass index (BMI) in the intensive
therapy had a mean weight gain of 17kg and their average
BMI increased from 24 to 31 [3]. Concomitant with their
excess weight gain, they developed components of the
metabolic syndrome, including central obesity and insulin
resistance.
The aim of this study was to identify genetic factors
that contribute to excess weight among T1D patients upon
intensive insulin therapy. We tested for association of this
trait with sequence variants in 8 candidate genes that are
implicated in obesity and/or T2DM (Table 1). The DCCT
study oﬀers a unique opportunity to ﬁnd such genes since
it is a large and very well characterized prospective study
of subjects with T1DM that have been exposed to inten-
sive therapy and experienced well-documented changes in
weight. Whereas there are many pathways to central obesity,
the weight gain due to intensive diabetes therapy in this
well-characterized DCCT cohort, represents a homogeneous
phenotype in which to search for central obesity genes.
2. Methods
2.1. Subjects. The DCCT was designed as a randomized
prospective trial to evaluate the beneﬁts of intensive diabetes
therapy with multiple insulin injections compared with
conventional therapy. A total of 1441 subjects, aged 13–39
years at baseline, 50% females and over 95% Caucasian,2 PPAR Research
Table 1: Candidate genes and SNPs analyzed for association with excess weight gain with intensive diabetes therapy. Genotyping was performed
using ABI TaqMan assays with the indicated ABI identiﬁcation numbers (custom, made to order). Minor allele frequencies are for Caucasian
populations derived from published data and the SNP database (http://www.ncbi.nlm.nih.gov/SNP/). PPARG, peroxisome proliferator
activatedreceptorγ;PPARGC1A,peroxisomeproliferator-activatedreceptorγ coactivator-1α;HSD11B1,11β-hydroxysteroid dehydrogenase
1; GR (NRC31), glucocorticoid receptor; GNB3, Gp r o t e i nβ3 subunit; ADIPOQ, adiponectin; NPY, neuropeptide y, FTO (aliases KIAA1752,
MGC5149), fat mass, and obesity-associated protein.
Gene Chromosomal location NCBI refSNP number TaqMan ABI assay ID Polymorphism Minor allele frequency
PPARγ2 3p25 rs1801282 1129864 Pro12Ala (exon 1) 0.10
PPARGC1A 4p15.1 rs8192678 Custom 1643184 Gly482Ser T/C (5  UTR) 0.34
rs2279525 0.31
11-β HSD1 1q32 rs2884090 2502457 C/T; intron 4 0.21
GR (NRC31) 5q34 rs6188 1046353 G/T; intron 5 0.31
rs11749561 178285 T/C; intron 3
GNB3 12p13 rs5443 2184734 C825T Silent/AS 0.30
ADIPOQ 3q27 rs266729 Custom 2412786 C-377G; promoter 0.29
NPY 7p15.1 rs5573 11164468 Ser22Ser 0.44
FTO 16q12.2 rs9939609 Custom 30090620 T to A in 3  UTR 0.43
were randomized to conventional or intensive therapy and
followed for 3.5–9 years (mean 6.5 years). Subjects in the
conventional therapy group [5] typically received one or
two insulin injections per day and had a quarterly follow-
up at their DCCT clinic. Intensive therapy subjects practiced
more rigorous diabetes management by taking three or more
insulin injections per day or using an insulin infusion pump,
self-monitored their blood glucose four or more times per
day, and visited their DCCT care providers monthly to
achieve HbA1c levels at least one percentage point lower than
the conventional therapy group. All enrolled subjects were in
good general health.
The 582 (48% females and 52% males) subjects in this
study were in the intensive therapy group and were 18 years
of age or older at DCCT entry [2]. They had previously been
divided into quartiles of change in BMI over the 6.2 years
of the DCCT [3]. The top quartile (Q4) of increase in BMI
in the intensive therapy had a mean weight gain of 17kg and
theiraverageBMIincreasedfrom24to31.Concomitantwith
their excess weight gain, they developed components of the
metabolic syndrome, including central obesity and insulin
resistance, which are strong risk factors for T2DM and for
familial combined hyperlipidemia [5].
2.2. Selection of Candidate Genes. Previous reports of linkage
and association of gene variants with obesity indices and/or
T2DM were the primary criteria in prioritizing the candidate
genes for this association study. In addition, priority was
given to genes that contain common variants with proven
functional consequences. Originally, 7 candidate genes were
chosen, and more recently the FTO (fat and obesity asso-
ciated protein) gene was added to this study because of
the recent ﬁndings that polymorphisms in this gene were
associated with obesity (see what follows).
The 8 candidate genes and the respective single
nucleotide polymorphisms that were tested for association
in this study are listed, in order of decreasing priority, in
Table 1. We previously showed that the Pro12Ala polymor-
phism in the peroxisome proliferator-activated receptorγ2
(PPARγ2), a transcription factor that is critical for adipo-
genesis, was associated with obesity and T2DM [6]. This
polymorphism is among a few that have been conﬁrmed to
be associated with T2DM [7]. A second good candidate gene
(PPARGCA1) encodes the PPRγ coactivator-1α (PGC-1α),
common variants which, particularly the Gly428Ser substi-
tution, were observed in some studies to be associated with
obesity and T2DM [8–10]. PGC-1α controls the expression
of a number of genes involved in energy homeostasis [11, 12]
that were shown to be coordinately reduced in individuals
with insulin resistance and T2DM [13, 14]. Polymorphisms
in the glucocorticoid receptor (GR) gene have been reported
to be associated with altered glucocorticoid sensitivity and
central obesity [15–17]. 11β-hydroxysteroid dehydrogenase
1( 1 1 β-HSD1) which plays an important role in determining
tissue glucocorticoid levels has also been implicated in
features of the metabolic syndrome in both humans and
transgenic mice by amplifying the eﬀects of glucocorticoid
action [18–20]. The gene encoding the G protein β3 subunit
(GNB3)wasconsideredasagoodcandidateforthemetabolic
syndrome and T2DM because it contains a common poly-
morphism (C825T) that was observed to be associated in
some studies with development of obesity in young indi-
v i d u a l sa c r o s sd i ﬀerent ethnic groups, body fat distribution
and hypertension. Furthermore, the T allele causes alternate
splicing with functional consequences [21–23]. A genome
wide scan for the metabolic syndrome detected signiﬁcant
linkage to chromosomal region 3q27 where the APM1 gene
encoding adiponectin is located [24]. Furthermore, genetic
variation in APM1 was observed to be associated with obe-
sity, insulin resistance [25], and T2DM [26]. Neuropeptide Y
(NPY) is a major regulator of food consumption and energy
homeostasis. Increased NPY signaling in the hypothalamus
leads to obesity and its complications such as T2DM and
cardiovasculardisease. Polymorphisms in the FTO gene werePPAR Research 3
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Figure 1: Association of the PPARGC1A Ser482 allele with weight
gain in all quartiles of males with T1DM on intensive diabetes
therapy. The frequency of the Ser allele in Q1 (N = 126) was 0.23;
Q2 (N = 172) was 0.34; Q3 (N = 158) was 0.38; Q4 (N = 102) was
0.45. The Ser allele was signiﬁcantly associated with a trend for
higherweightgainwithaP-valueof.004(Chi-squarewith3degrees
of freedom), and a P-value of .0004 (trend, Cochran-Armitage).
shown by a genome-wide association analysis [27]t ob e
associated with BMI and with predisposition to childhood
and adult obesity (reviewed in [28]).
2.3. Genotyping. DNA samples from the subjects were
prepared from peripheral white blood cells at the Dia-
betes/Endocrine Research Center at the University of Wash-
ington, USA. Single nucleotide polymorphism (SNP) geno-
typing was performed by real-time PCR ampliﬁcation on an
AppliedBiosystems(ABI)3500apparatususingABITaqMan
assays purchased from the manufacturer. The ABI assay
identiﬁcation numbers are given in Table 1.
2.4. Statistical Analysis. The frequency of alleles and geno-
types were compared in Q1 and Q4 by the chi-square
(χ2) test. Bonferroni corrections to the signiﬁcance of
associations of the PGC1α Gly482Ser polymorphism with
weight gain were not made because of our study design
that placed PPARγ2a n dPGC1α as top priority candidate
genes (Table 1) .A l lo ft h eg e n e sw et e s t e dh a da l r e a d yb e e n
reported to be associated with either T2DM or obesity.
3. Results
A total of 252 DCCT non-Hispanic white North American
subjects (141 females and 111 males) comprising the upper
and lower quartiles of weight gain with intensive therapy
were initially genotyped, in a double-blinded manner, for a
single common SNP in each of 7 candidate genes (Table 1).
The subjects were originally stratiﬁed into quartiles regard-
less of gender. Quartile 1 (Q1) had 64 females and 63 males
gained the least amount of weight and quartile 4 (Q4) had
85 females and 51 males and gained the highest amount of
weight. Allelic and genotypic frequencies were initially com-
pared between Q1 and Q4 regardless of gender. The results
of this analysis revealed a signiﬁcant diﬀerence in allelic
and genotypic frequencies of the Gly482Ser polymorphism
(rs8192678) in PPARGC1A. The Gly/Gly genotype frequency
was 0.49 and 0.32 in Q1 and Q4, respectively, (P = .028)
and the Gly/Ser genotype was 0.42 and 0.58 in Q1 and Q4,
respectively, (P = .028). The genotypic distributions were
in Hardy-Weinberg equilibrium (P = .25). The frequency of
the Ser allele was 0.30 and 0.39 in Q1 and Q4, respectively,
(P = .08). The frequencies of alleles and genotypes in all
other 6 candidate genes were not signiﬁcantly diﬀerent
between Q1 and Q4.
Next, we asked whether gender plays a role in the
observed association. Interestingly, we found that the
Gly482Ser polymorphism in PPARGC1A was associated with
weight gain on intensive diabetes therapy only in males
(Table 2). The frequency of the Ser allele in males of Q1
was 0.23 compared to 0.45 in males of Q4 (P = .005). The
Ser allele frequency was almost identical in females of Q1
and Q4. As expected, the frequencies of genotypes in males
were also signiﬁcantly diﬀerent between the two quartiles
(Table 2). No other covariates were tested for association of
the polymorphisms with weight gain.
In an attempt to validate the above association, we
genotyped male subjects belonging to Q2 and Q3 for the
Gly482Serpolymorphismandexaminedtheassociationwith
the extent of weight gain on intensive diabetes therapy in all
quartiles. The results are plotted in Figure 1. The frequency
of the Ser allele in Q1 (N = 126) was 0.23; Q2 (N = 172)
was 0.34; Q3 (N = 158) was 0.38; Q4 (N = 102) was 0.45.
As observed with Q1 and Q4, the Ser allele was signiﬁcantly
associated with a trend for higher weight gain with a P-value
of.004(Chi-squarewith3degreesoffreedom),andaP-value
of .0004 (trend, Cochran-Armitage).
No signiﬁcant diﬀerences in allele and genotype diﬀer-
ences between Q1 and Q4 in either males or females were
found for the rest of the candidate genes. The Gly482Ser
polymorphism is widespread among various ethnic groups.
ThefrequencyoftheSerallelewasreportedtobe0.34among
Germans [10], 0.30 among Danes [8], 0.34 among European
Americans (this study), 0.13 among African Americans
(unpublished data from our laboratory), 0.18 among Pima
Indians [29], 0.43 among Japanese [9], and 0.39 among
Chinese (dbSNP at http://www.ncbi.nlm.nih.gov/SNP/).
Subsequently, we assessed the association of a second
polymorphism (rs 2279525) located in the 5  untranslated
region (5  UTR) of the PGC-1α gene (Figure 2). No
association with weight gain was observed in either males
or females (Table 2). This polymorphism is approximately
46.6KB upstream of the Gly482Ser polymorphism [30],
and the two polymorphisms are in linkage equilibrium
(http://www.hapmap.org/ and our data).
4. Discussion
We found that the common and widespread Gly482Ser
polymorphism in PGC1α is signiﬁcantly associated with
excessive weight gain in male but not female subjects with
T1DM who had undergone intensive diabetes therapy. The
less common Ser allele was associated with a higher level4 PPAR Research
Table 2: Genotype and allele frequencies of the variants in candidate genes examined for association with weight gain by DCCT subjects on
intensive diabetes therapy. N, number of subjects; the P-values compare genotype and minor allele frequencies between quartile 1 (Q1) and
quartile 4 (Q4) of weight gain; NS, statistically not signiﬁcant. The brackets indicate that heterozygotes and homozygotes for the minor allele
were combined for comparisons between quartiles.
Gene/polymorphism Frequency in females Frequency in males
Q1 (N,% ) Q 4( N,% ) P Q1 (N,% ) Q 4( N,% ) P
PPARG2
Pro/Pro 52 (82.5) 62 (78.5) NS 45 (75.0) 42 (84.2) NS
Pro/Ala 11 (17.5) 17 (21.5) NS 15 (25.0) 9 (17.6) NS
Ala/Ala 0 (0) 0 (0) 0 (0) 0 (0) NS
Allele frequency 0.09 0.11 NS 0.13 0.09 NS
PPARGC1A
Gly/Gly 25 (40.3) 30 (38.0) NS 35 (58.3) 12 (23.5) .0054
Gly/Ser

28(45.2)
9(14.5)
43(54.4)
6(7.6)

NS

22(36.7)
3(5.0)
32(62.8)
7(13.7)

.0131
Ser/Ser
Frequency of Ser 0.37 0.35 NS 0.23 0.45 .0050
PPARGC1A
T/ T 28 (45.2) 35 (44.9) NS 25 (42.3) 28 (54.9) NS
T/  C

27(43.5)
7(11.3)
38(48.7)
5(6.4)

NS

26(44.1)
8(13.6)
19(37.3)
4(7.8)

NS
C/C
Frequency of C 0.33 0.30 NS 0.35 0.27 NS
HSD11B1
C/C 41 (66.1) 50 (59.5) NS 42 (66.7) 32 (62.7) NS
C/T

18(29.0)
3(4.9)
28(33.3)
6(7.2)

NS

16(25.4)
5(7.9)
17(33.3)
2(4.0)

NS
T/T
Frequency of T 0.19 0.23 NS 0.21 0.21 NS
GNB3
C/C 34 (54.8) 35 (44.3) NS 30 (50.0) 28 (54.9) NS
C/T

23(37.1)
5(8.1)
33(41.8)
11(13.9)

NS

23(38.3)
7(11.7)
19(37.3)
4(7.8)

NS
T/T
Frequency of T 0.27 0.35 NS 0.31 0.27 NS
NRC31
G/G 27 (42.2) 41 (52.6) NS 29 (48.3) 25 (49.0) NS
G/T

29(45.3)
8(12.5)
34(43.6)
3(3.8)

NS

22(36.7)
9(15.0)
25(49.0)
1(2.0)

NS
T/T
Frequency of T 0.35 0.26 NS 0.33 0.27 NS
ADIPOQ
C/C 32 (52.5) 49 (62.0) NS 32 (53.3) 30 (58.8) NS
C/G

22(36.1)
7(11.4)
24(30.4)
6(7.6)

NS

26(43.4)
2(3.3)
17(33.3)
4(7.9)

NS
G/G
Frequency of G 0.30 0.23 NS 0.25 0.25 NS
NPY
G/G 19 (30.6) 21 (26.6) NS 15 (25.0) 10 (19.6) NS
G/A

29(46.8)
14(22.6)
34(43.0)
24(30.4)

NS

32(53.3)
13(21.7)
27(52.9)
14(27.5)

NS
A/A
Frequency of A 0.46 0.52 NS 0.48 0.54 NS
FTO
TT 23 (36.0) 29 (35.0) NS 16 (25.4) 13 (27.1) NS
TA 32 (50.0) 40 (48.2) NS 35 (55.6) 25 (52.1) NS
AA 9 (14.0) 14 (17.0) NS 12 (19.0) 10 (20.8) NS
Frequency of A 0.39 0.41 NS 0.47 0.47 NSPPAR Research 5
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Figure 2: Structure of the PPARGC1A gene showing location of
linkage disequilibrium (LD) blocks and sequence polymorphisms.
of weight gain. Subjects who gained excessive weight had
a higher frequency of T2DM among their parents. Therefore,
we hypothesized that the Gly482Ser polymorphism may lead
to excessive weight gain in DCCT via its association with the
metabolic syndrome and T2DM.
PGC1α is a powerful transcriptional coactivator of
several nuclear receptors, including PPARγ, that regulate
key metabolic steps in energy homeostasis and glucose
metabolism. The level of PGC1α mRNA in skeletal muscle
was observed to be lower in individuals with insulin resis-
tanceandT2DM[31].Inaddition,theexpressionofPGC1α-
responsive genes involved in oxidative phosphorylation is
reduced in skeletal muscle of individuals with T2DM, their
healthy ﬁrst degree relatives and even those with impaired
glucose tolerance [13, 14]. Importantly, PGC1α mRNA levels
in skeletal muscle were lower among carriers of the Ser482
allele [31]. Therefore, it is likely that PGC1α with Ser at
position 428 is a less eﬃcient coactivator of transcription
factors, including those that regulate the PPARGC1A gene
itself [32]. Therefore, lower PGC1α activity levels may lead
to lower levels of glucose and fatty acid oxidation and to fat
accumulation [14].
In this study, the Ser482 allele predicted excessive weight
gain with intensive diabetes therapy in males, but not in
females. Two studies have also reported a gender-speciﬁc
association of the Ser allele with obesity. Ridderstr˚ ale et al.
reported association of the Ser allele with increased risk
of obesity in physically inactive men over 50 years of age,
but not in women [33]. However, in another study [10]
the association was observed in middle-aged women but
not men. The reason for this conﬂicting result could be
attributed to the older age of subjects than those in DCCT,
for example, the above middle-aged women could have
been postmenopausal. Also, our subjects had T1DM and
their weight gain was due speciﬁcally to intensive diabetes
therapy. The Ser allele was also found to be associated
with T2DM in Northern Chinese, especially in males [34].
We do not have an explanation for the gender-speciﬁc
association. One possibility is that activity levels of PGC1α
may be coregulated by estrogens. This is compatible with
the observation that the level of muscle PGC1α mRNA is
lower in females than males [31]. Therefore, eﬀects of the
Gly482Ser polymorphism on weight gain may be attenuated
by the action of estrogens.
The following genetic association studies support the
hypothesis that the PGC1α Gly482Ser polymorphism aﬀects
weight gain via its eﬀect on the metabolic syndrome (which
includes insulin resistance and abdominal obesity) and
T2DM. First, a meta-analysis showed a modest association
of the Ser482 allele with the risk for T2DM [35]. These
case-control study populations included both males and
females (3,718 cases and 4,818 controls) that were, unfor-
tunately, not independently tested for association. Second,
a locus on chromosome 4p15.1, where the PPARGC1A
is located, was found to be associated with abdominal
obesity [36] and insulin resistance [37]. Third, the PPARγ2
Pro12Ala and the PGC1α Gly482Ser polymorphisms were
associated with conversion from impaired glucose tolerance
to T2DM in the STOP-NIDDM trial [38]. The PPARγ2
Pro12Ala polymorphism has been consistently shown to
be associated with risk for T2DM [6, 7, 39]. Fourth, The
Gly482Ser polymorphism is located in a highly conserved
domain that was shown to interact with and coactivate
the muscle enhancer factor 2C that activates the GLUT4
gene [40]. Importantly, the Ser482 allele was consistently
observed to be associated with insulin resistance, T2DM
or obesity. This monoallelic association in diﬀerent pop-
ulations represents a strong validation for this associa-
tion.
Haplotype analysis at the PPARGC1A gene locus in
Caucasians revealed the existence of 4 adjacent multi-SNP
linkage disequilibrium (LD) blocks with a D  of close
to 1 (Figure 2)( http://www.hapmap.org/). The Gly482Ser
polymorphism lies within the 16.2KB LD block. This block
contains 10 haplotypes based on 8 single-SNP genotypes
(http://www.broad.mit.edu/mpg/haploview/). Only one
haplotype contains the Ser allele and is the most common
one (0.367). The other seven haplotypes have Gly, the most
common (0.224) diﬀers from the Ser-containing haplotype
at 8 of the 13 SNPs. Therefore, it is possible that variants
in LD with the Ser allele could contribute to the observed
association. Another polymorphism in exon 9 (Thr612Met)
(Figure 2) that lies within the 16.2KB LD block could
also inﬂuence the activity of PGC1α [8]. However, its
frequency is quite low in the general population (Met allele
frequency of 0.03) and, therefore, is unlikely to have a
major impact on the observed association with the Ser482
allele.
The polymorphism in the 5  untranslated region of
PPARGC1A (Figure 2) was not associated with weight gain
in either sex in our study. Since this polymorphism is in LD
with those in exon 1, our result is consistent with lack of
association between the Ser74Leu polymorphism in exon 2
(Figure 2) and T2DM [8].
No signiﬁcant association of variants in the other 7
candidate genes was observed. This does not mean that
these genes do not contribute to excessive weight gain.
The relatively small sample size and the low frequency
of some of the polymorphisms may have resulted in low
power to detect an association. A more thorough analysis
of other variants in these genes is necessary using a larger
population sample in order to detect moderate eﬀects on
weight gain.6 PPAR Research
5. Conclusions
The common PGC1α-Gly482Ser polymorphism was signiﬁ-
cantly associated with excessive weight gain in male, but not
female subjects with T1DM who had undergone intensive
diabetes therapy. The less common Ser allele was associated
withahigherlevelofweightgain.PGC1αSerisalesseﬃcient
coactivator of transcription factors. Therefore, lower PGC1α
activity levels may lead to lower levels of glucose and fatty
acid oxidation and to fat accumulation.
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